DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study

被引：2
|
作者：
Janku, F. [1 ]
George, S. [2 ]
Razak, A. [3 ]
Gordon, M. [4 ]
Brooks, D. [5 ]
Flynn, D. G. [6 ]
Kaufman, M. [6 ]
Pitman, J. [5 ]
Smith, B. [6 ]
Somaiah, N. [7 ]
Gerstenberger, E. [8 ]
Westwood, D. [5 ]
Rosen, O. [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02215 USA
[3] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[4] Pinnacle Oncol Hematol, Phase Unit 1, Scottsdale, AZ USA
[5] Deciphera Pharmaceut, Clin Res & Dev, Waltham, MA USA
[6] Deciphera Pharmaceut, Res, Lawrence, KS USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
[8] Veristat, Biostat, Southborough, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32613-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7LBA
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [1] Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor
    Janku, Filip
    Razak, Albi
    Gordon, Michael
    Brooks, David
    Flynn, Daniel
    Gupta, Anu
    Kaufman, Michael
    Leary, Cynthia
    Smith, Bryan
    Westwood, Deb
    Somaiah, Neeta
    Helman, Elena
    Gerstenberger, Eric
    Rosen, Oliver
    George, Suzanne
    CANCER RESEARCH, 2017, 77
  • [2] DCC-2618, A NOVEL PAN-KIT AND PDGFRA KINASE SWITCH CONTROL INHIBITOR, SHOWS ENCOURAGING SIGNAL IN A PATIENT (PT) WITH GLIOBLASTOMA (GBM)
    de Groot, John
    George, Suzanne
    Razak, Albiruni
    Gordon, Michael
    Janku, Filip
    Ligon, Keith
    Wen, Patrick
    Friedlander, Sharon
    Flynn, Daniel
    Kaufman, Michael
    Pitman, Jama
    Ruiz-Soto, Rodrigo
    Smith, Bryan
    Westwood, Deborah
    Rosen, Oliver
    Reardon, David
    NEURO-ONCOLOGY, 2017, 19 : 1 - 1
  • [3] Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
    Smith, Bryan D.
    Kaufman, Michael D.
    Lu, Wei-Ping
    Gupta, Anu
    Leary, Cynthia B.
    Wise, Scott C.
    Rutkoski, Thomas J.
    Ahn, Yu Mi
    Al-Ani, Gada
    Bulfer, Stacie L.
    Caldwell, Timothy M.
    Chun, Lawrence
    Ensinger, Carol L.
    Hood, Molly M.
    McKinley, Arin
    Patti, William C.
    Ruiz-Soto, Rodrigo
    Su, Ying
    Telikepalli, Hanumaiah
    Town, Ajia
    Turner, Benjamin A.
    Vogeti, Lakshminarayana
    Vogeti, Subha
    Yates, Karen
    Janku, Filip
    Razak, Albiruni Ryan Abdul
    Rosen, Oliver
    Heinrich, Michael C.
    Flynn, Daniel L.
    CANCER CELL, 2019, 35 (05) : 738 - +
  • [4] The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
    Schneeweiss, Mathias
    Peter, Barbara
    Bibi, Siham
    Eisenwort, Gregor
    Smiljkovic, Dubravka
    Blatt, Katharina
    Jawhar, Mohamad
    Berger, Daniela
    Stefanzl, Gabriele
    Herndlhofer, Susanne
    Greiner, Georg
    Hoermann, Gregor
    Hadzijusufovic, Emir
    Gleixner, Karoline V.
    Bettelheim, Peter
    Geissler, Klaus
    Sperr, Wolfgang R.
    Reiter, Andreas
    Arock, Michel
    Valent, Peter
    HAEMATOLOGICA, 2018, 103 (05) : 799 - 809
  • [5] Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.
    Janku, Filip
    Razak, Albiruni Ryan Abdul
    Gordon, Michael S.
    Brooks, David Glenn
    Flynn, Daniel Lee
    Kaufman, Michael
    Pitman, Jama
    Smith, Bryan Douglas
    Somaiah, Neeta
    De Groot, John Frederick
    Chen, Guo
    Jennings, Julia
    Salah, Samer
    Westwood, Deb
    Gerstenberger, Eric
    Rosen, Oliver
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Encouraging activity of novel pan-KIT and PDGFRa inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)
    Janku, F.
    Razak, A. R. A.
    Gordon, M. S.
    Flynn, D.
    Kaufman, M.
    Pitman, J.
    Smith, B.
    Somaiah, N.
    Jennings, J.
    Salah, S.
    Westwood, D.
    Greensmith, D.
    Jacobson, J.
    Rosen, O.
    George, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Vagal Neuromodulation on Ventricular Mechanics in Takotsubo Syndrome: A First-in-Human Proof-of-Concept Study
    Nagai, Michiaki
    Yoshitomi, Yuki
    Kato, Masaya
    Oda, Noboru
    Dote, Keigo
    Po, Sunny S.
    Dasari, Tarun W.
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (05) : e611 - e614
  • [8] THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS
    Schneeweiss, M.
    Peter, B.
    Bibi, S.
    Blatt, K.
    Jawhar, M.
    Berger, D.
    Stefanzl, G.
    Herndlhofer, S.
    Sperr, W. R.
    Hadzijusufovic, E.
    Gleixner, K. V.
    Reiter, A.
    Arock, M.
    Valent, P.
    HAEMATOLOGICA, 2017, 102 : 276 - 277
  • [9] Novel Neuromodulation Approach to Improve Left Ventricular Contractility in Heart Failure A First-in-Human Proof-of-Concept Study
    Reddy, Vivek Y.
    Petru, Jan
    Malek, Filip
    Stylos, Lee
    Goedeke, Steve
    Neuzil, Petr
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2020, 13 (11): : E008407
  • [10] Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
    Talbot, Denis C.
    Ranson, Malcolm
    Davies, Joanna
    Lahn, Michael
    Callies, Sophie
    Andre, Valerie
    Kadam, Sunil
    Burgess, Michael
    Slapak, Christopher
    Olsen, Anna L.
    McHugh, Peter J.
    de Bono, Johann S.
    Matthews, Julian
    Saleem, Azeem
    Price, Patricia
    CLINICAL CANCER RESEARCH, 2010, 16 (24) : 6150 - 6158
12345